PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

Table 1

Baseline clinical characteristics of the study participants.

Parameters	Group A; ()	Group B; ()	P value
Sex (M/F)	19/6	28/12	0.599
Age (years)	53.76 ± 8.89	49.10 ± 10.57	0.071
BMI (kg/m^2)	26.46 ± 4.60	24.63 ± 3.71	0.083
SBP (mmHg)	125.00 ± 7.65	123.63 ± 9.00	0.529
DBP (mmHg)	74.24 ± 8.74	73.75 ± 6.13	0.808
FBG (mmol/L)	7.43 ± 1.01	5.06 ± 0.50	<0.001
TC (mmol/L)	4.62 ± 0.66	4.49 ± 0.74	0.461
HDL (mmol/L)	1.25 ± 0.29	1.61 ± 0.29	<0.001
LDL (mmol/L)	2.80 ± 0.53	2.45 ± 0.62	0.023
TG (mmol/L)	3.05 ± 0.86	0.92 ± 0.37	<0.001
HbA1c (%)	6.88 ± 0.72	5.42 ± 0.33	<0.001

Group A, type 2 diabetes mellitus patients with hypertriglyceridemia; group B, control subjects; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HbA1c, glycosylated hemoglobin.